Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 436 participants.

Also called NCT07030621

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 436 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07030621
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07030621. Randomized; double masking; primary purpose treatment. Start 2025-07-01 (anticipated); primary completion 2027-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
Acronym
STARS
Condition
Acute Ischemic Stroke
Intervention (Drug)
Semaglutide 0.5 mg
Intervention (Drug)
Normal Saline
Lead sponsor
RenJi Hospital (class: other)

Record details

Record id
cardio:ct-nct07030621
Content hash
b73f1855e192bd512b41deb491ac9b102057974267b692ffc3355b61fdf72516